Statistics from Altmetric.com
P13 HIGHLY SENSITIVE ASSAY TO DETECT HEPCIDIN IN BIOLOGICAL FLUIDS: PRESENCE OF HEPCIDIN IN PLEURAL FLUID
1A. Sangwaiya, 1J. D. Arnold, 1V. Manglam, 2M. Thursz, 1F. Geoghegan, 3M. Busbridge. 1Ealing Hospital NHS Trust, London, UK, 2St Mary’s Hospital NHS Trust, London, UK, 3Hammersmith Hospital NHS Trust, London, UK
Introduction: Hepcidin is a 25 aminoacid cysteine-rich peptide predominantly formed in the liver. It acts as a central iron regulator in humans but as an antimicrobial peptide in other species. It has been proposed that hepcidin causes anaemia of chronic inflammation by suppressing iron export via ferroportin channels in macrophages, enterocytes and kupffer cells. Due to its dual role, hepcidin is a novel peptide to study. We report the levels of hepcidin in pleural fluids due to various causes.
Patients and Methods: 11 participants with pleural effusion were recruited from a single hospital with mixed ethnicity, predominantly Caucasians and south Asians. Pleural fluid was obtained for routine investigations and divided into two cohorts using Light’s criteria as exudate or transudate. Serum was collected from 25 healthy volunteers. Hepcidin-25 was measured using a novel robust radioimmunoassay developed in-house at the clinical chemistry department at Hammersmith Hospital.
Results: The mean hepcidin in exudate (n = 8, M:F 5:3) was 80.87±103.55 ng/ml (median 40.47, SE 36.61). The mean total protein level exudate was 44.31 g/l. The mean hepcidin in transudate (n = 3, M:F 2:1) was 16.71±6.68 ng/ml (median 18.9, SE 3.85). The mean total protein in transudate was <25 g/l. The mean serum hepcidin in healthy volunteers (n = 25, M:F 11:14) was 15.30±15.71 ng/ml.
Conclusion: We provide evidence for the first time presence of hepcidin in pleural fluid. A higher trend of hepcidin in exudate pleural fluid has been observed which may be a part of innate immunity preserved over evolution. More studies are needed to confirm its role and biological activity in pleural fluid.
P14 PREVENTION OF SKIN METASTASIS IN MALIGNANT MESOTHELIOMA WITH PROPHYLACTIC IRRADIATION OF TRACTS (PIT): IS THE DIFFERENCE IN RESEARCH EVIDENCE DUE TO THE DISCREPANCY BETWEEN THE DISTANCE FROM PLEURAL ENTRY POINT AND THE SKIN SCAR?
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.